EAM
RYTM icon

Exome Asset Management’s Rhythm Pharmaceuticals RYTM Stock Holding History

Exome Asset Management’s Portfolio RYTM Stock Details RYTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-40,000
Closed -$70K – 79
2025
Q1 		$70K Buy
+40,000
New +$2.22M 0.06% 53

Other funds holding RYTM

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

Exome Asset Management's RYTM Position: Q1 2026 in Review

Exome Asset Management opened a new position in Rhythm Pharmaceuticals (RYTM) in Q1 2026: 40,581 shares worth $3.53M. The stake represents 1.83% of the portfolio and ranks #19 among its holdings. This is a return to the name: Exome Asset Management previously reported a position in RYTM as recently as Q1 2024.

Exome Asset Management first reported a position in RYTM in Q4 2023 and has held it in 3 quarters since. 285 funds tracked by Wall St. Rank hold RYTM as of Q1 2026.

  • Exome Asset Management held 40,581 shares of Rhythm Pharmaceuticals worth $3.53M as of Q1 2026.
  • Rhythm Pharmaceuticals was a new Exome Asset Management position in Q1 2026.
  • Rhythm Pharmaceuticals made up 1.83% of Exome Asset Management's portfolio in Q1 2026, its #19 holding.
  • Exome Asset Management first reported a position in Rhythm Pharmaceuticals in Q4 2023 and has held it in 3 quarters since.
  • 285 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q1 2026.

Based on Exome Asset Management's 13F filing for Q1 2026, filed 15 May 2026.